How does Entresto (sacubitril/valsartan) affect people with kidney problems?
Entresto can be used in patients with renal impairment, but kidney function and blood pressure can change after starting treatment. In people with reduced kidney function, clinicians typically monitor for worsening renal function and for electrolyte or blood-pressure issues, especially during dose titration.
Can I take Entresto if I have chronic kidney disease (CKD)?
Yes, but dosing and monitoring depend on how impaired kidney function is. Patients with more advanced CKD generally require closer follow-up because medication effects (on kidney filtration and potassium balance) can be more pronounced.
What happens to creatinine and potassium when starting Entresto in renal impairment?
With renal impairment, the main clinical concerns after starting or increasing Entresto are:
- Kidney function changes (often tracked with serum creatinine and estimated glomerular filtration rate).
- Potassium changes (hyperkalemia risk is a key concern with medicines in the RAAS pathway, which includes valsartan).
Clinicians watch these labs after initiation and during dose changes.
Is Entresto safe in acute kidney injury or severe renal impairment?
In acute or rapidly worsening kidney function (for example, acute kidney injury), clinicians usually reassess whether Entresto is appropriate and may hold or adjust therapy depending on the cause of the kidney decline and the patient’s hemodynamic status (blood pressure, volume status). Severe renal impairment increases the need for individualized monitoring.
Does renal impairment change Entresto dosing recommendations?
Entresto dosing is individualized. Kidney impairment can influence how aggressively a clinician titrates the dose and how frequently labs are checked. The practical approach is to start and adjust in a way that avoids significant drops in blood pressure and significant rises in potassium or creatinine.
What monitoring should patients with kidney disease expect?
Typical follow-up focuses on:
- Blood pressure (to detect symptomatic hypotension).
- Serum creatinine/eGFR (to detect worsening kidney function).
- Potassium (to detect hyperkalemia).
Monitoring is usually most frequent at the start and after dose adjustments.
What symptoms should trigger urgent contact in renal impairment?
Patients should seek prompt medical advice if they develop signs that could reflect low blood pressure or dangerous electrolyte changes, such as dizziness/fainting, severe weakness, palpitations, or worsening shortness of breath. Any significant lab deterioration should also prompt contact with the prescribing clinician.
Where can I check patent/exclusivity and related product details?
For background on Entresto and market exclusivity/patent issues (which can affect availability of formulations and generics), see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/entresto
Sources
- https://www.drugpatentwatch.com/p/entresto